Barcellona D, Biondi G, Mameli G, Marongiu F
Istituto di Medicina Interna, University of Cagliari, Italy.
Int J Clin Lab Res. 1997;27(1):76-8. doi: 10.1007/BF02827248.
We investigated the behavior of prothrombin fragment F1 + 2 and thrombin-antithrombin complexes in 70 patients treated with chronic anticoagulant therapy. Moreover, in a longitudinal study 37 patients were evaluated twice and 16 patients three times. Twenty-eight age- and sex-matched healthy subjects were also studied as a control group. Prothrombin fragment F1 + 2 or thrombin-antithrombin values among patients with different International Normalized Ratios, nor in the same patients studied two or three times. Our results confirm that oral anticoagulant treatment can effectively reduce thrombin activity. However, strong anticoagulation does not induce a further significant decrease in fragment F1 + 2 values. Therefore, we feel measurement of fragment F1 + 2 might be less useful than thought in optimizing oral anticoagulant therapy.
我们研究了70例接受慢性抗凝治疗患者的凝血酶原片段F1 + 2和凝血酶 - 抗凝血酶复合物的情况。此外，在一项纵向研究中，37例患者接受了两次评估，16例患者接受了三次评估。还研究了28名年龄和性别匹配的健康受试者作为对照组。不同国际标准化比值的患者之间，以及同一患者接受两次或三次研究时，凝血酶原片段F1 + 2或凝血酶 - 抗凝血酶的值均无差异。我们的结果证实，口服抗凝治疗可有效降低凝血酶活性。然而，强效抗凝并不会导致片段F1 + 2值进一步显著降低。因此，我们认为在优化口服抗凝治疗中，测量片段F1 + 2可能不如预期有用。
